Dr Reddy's Laboratories, an integrated global pharmaceutical company, today reported a fall of 15.64% in its consolidated net profit for the fourth quarter.
 
It earned profit of Rs 4.81 billion for the quarter ended Mar. 31, 2014 compared with Rs 5.71 billion, a year ago.

Net income came at Rs 34.80 billion, an increase of 4.22% over Rs 33.39 billion in the same period a year ago.

Analysts, on average, expected Dr Reddys Lab to report a profit of Rs 5.79 billion, on revenue of Rs 36.57 billion.

During the quarter, the company launched 13 new generic products, filed 22 new product registrations and 29 DMFs globally in Q4 FY14.

Shares of the company declined Rs 60.6, or 2.23%, to trade at Rs 2,658.55. The total volume of shares traded was 41,292 at the BSE (2.02 p.m., Tuesday).